Ireland's HSE approves funding for Friedreich's ataxia treatment

The Irish Health Service Executive (HSE) has approved reimbursement for omaveloxolone, a life-changing drug for patients with Friedreich's ataxia. This decision marks a significant shift in access for rare disease patients in Ireland, though the long-term fiscal impact on the national health budget remains to be assessed.